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ABSTRACT 
Obesity is a major factor associated with inflammatory and various metabolic syndromes. Etlingera caloprhys, an 
Indonesia plant native from Southeast Sulawesi, is traditionally used years as daily food ingredient by local communities. 
The present paper presents an in vitro and in vivo study related to the anti-obesity effects of Etlingera caloprhys ethanol 
extract (ECEE). An experiment was conducted to evaluate in vitro pancreatic lipase enzyme (PLE) inhibition and in vivo 
anti-obesity activity in high fat diet (HFD) induced obese zebrafish fed with 10% w/w and 20% w/w ECEE-HFD were 
evaluated. To confirm anti-obesity activity, a set of obesity and biochemistry parameters i.e. body weight, body mass 
index (BMI), triglyceride and blood glucose levels, were monitored. Additionally, gene expression levels related to 
obesity i.e. adiponectin and PPARγ in visceral adipose tissue (VAT) were also evaluated. The results showed that ECEE 
significantly (p <0.05) inhibited PLE activity with an inhibition concentration (IC)50 of below 100 µg/mL. The HFD 
induced obese zebrafish fed with 10% w/w and 20% w/w ECEE-HFD showed decreasing body weight and BMI. The 
biochemistry parameters of the HFD-induced obese zebrafish fed with 10% w/w ECEE-HFD obviously displayed optimum 
reduction of triglycerides and blood glucose levels. More importantly, the gene expression confirmed that ECEE 
suppressed adipogenesis in VAT. Hence, ECEE is suggested as a potent alternative medicine for prevention of metabolic 
syndromes related to obesity.
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ABSTRAK
Keobesan adalah faktor utama yang dikaitkan dengan radang dan pelbagai sindrom metabolisme. Etlingera calophrys, 
tumbuhan asli Indonesia dari Sulawesi Tenggara, secara tradisinya digunakan selama bertahun-tahun sebagai bahan 
makanan harian oleh masyarakat tempatan. Kertas ini membentangkan kajian secara in vitro dan in vivo yang berkaitan 
dengan kesan anti-keobesan daripada ekstrak etanol Etlingera calophrys (ECEE). Satu uji kaji telah dijalankan untuk 
menilai perencatan enzim lipase pankreas (PLE) dan aktiviti anti-keobesan secara in vivo dalam diet teraruh lemak 
tinggi (HFD) daripada ikan zebra obes yang diberi makan 10% w/w dan 20% w/w ECEE -HFD telah dinilai. Untuk 
mengesahkan aktiviti anti-keobesan, satu set keobesan dan parameter biokimia iaitu berat badan, indeks jisim badan 
(BMI), trigliserida dan paras glukosa darah telah dipantau. Selain itu, tahap ekspresi gen yang berkaitan dengan 
keobesan iaitu adiponektin dan PPARγ dalam tisu adipos visera (VAT) juga dinilai. Hasil kajian menunjukkan bahawa 
ECEE dengan ketara (p < 0.05) merencat aktiviti PLE dengan kepekatan perencatan (IC)50 di bawah 100 μg/mL. HFD 
teraruh ikan zebra obes diberi makan 10% w/w dan 20% w/w ECEE-HFD menunjukkan penurunan berat badan dan 
BMI. Parameter biokimia daripada HFD teraruh ikan zebra obes yang diberi makan 10% w/w ECEE-HFD jelas 
menunjukkan pengurangan optimum trigliserida dan paras glukosa darah. Lebih penting lagi, pengekspresan gen 
mengesahkan bahawa ECEE menghalang adipogenesis dalam VAT. Oleh itu, ECEE dicadangkan sebagai ubat alternatif 
yang mujarab untuk mencegah sindrom metabolik yang berkaitan dengan keobesan.
Kata kunci: Anti-keobesan; Etlingera calophrys; ikan zebra; lipase pankreas
INTRODUCTION
Obesity is a condition of excess body weight due to 
overconsumption of high calory-food combined with low 
levels of physical activity, resulting in a fat accumulation 
in several body parts (Baqai & Wilding 2015). Obesity is 
associated with several metabolic syndromes including 
type 2 diabetes mellitus (T2DM), insulin resistance, 
dyslipidemia, cardiovascular disease, as well as 
atherosclerosis as an impact of adipokine secretion from 
adipose tissue (Cabezas et al. 2013; Redinger 2007). 
Obesity is a health concern both in developed and 
developing countries. The World Health Organization 
(WHO) estimates that more than 1.9 billion adults (age 18 
years and over) are overweight, and 600 million of these 
adults are obese (WHO 2014). In addition, about 4 million 
deaths globally are due to cardiovascular disease or 
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diabetes mellitus associated with a high body mass index 
(BMI) (Afshin et al. 2017). 
Orlistat is a first line conventional drug to treat obesity; 
however, this drug has undesirable side effects, such as 
nausea, vomiting, constipation, headache, insomnia, 
stomachache, as well as gastrointestinal disturbance (Balaji 
et al. 2016; Pucci & Finner 2015). Unlike conventional 
drug therapy, herbal medicines have lower adverse effects 
(Moreira et al. 2014). Hence, natural products are expected 
to be safer and offer fewer side effects in treating obesity.
 Etlingera calophrys (K.Schum.) A.D. Poulsen 
(Zingiberaceae) is also known as olae. It is native from 
Southeast Sulawesi, Indonesia. Traditionally, the leaves of 
EC are used for tightening the stomach post-partum. The 
rhizomes are used as spice (Ruslin & Sahidin 2008). 
Sahidin et al. (2018) have explored the potency of the EC 
stem and have identified yakuchinone A as a bioactive 
compound with strong antioxidant activity. Interestingly, 
a study on yakuchinone A reported its potency to suppress 
gene expression related to obesity involving leptin and 
peroxisome proliferator-activated receptor-γ (PPARγ). 
Additionally, yakuchinone A also suppresses lipid 
accumulation during adipocyte differentiation in 3T3-L1 
cells (Lin et al. 2013). Some studies have reported that 
different parts of the plant exhibit similar bioactivity, for 
example the leaves, peels and seeds from Punica granatum 
can potentially be used in the treatment of obesity (Hossin 
2009; Lei et al. 2007; Vroegrijk et al. 2011). Thus, we 
hypothesized that EC rhizomes have anti-obesity activity 
in a similar manner as the EC stem. 
Anti-obesity analysis can be carried out on a rat model 
or a zebrafish model. The zebrafish is a small organism 
that has been used in many scientific investigations related 
to biological activity including obesity, diabetes mellitus, 
dyslipidemia and atherosclerosis (Schlegel 2016; Zang et 
al. 2018). The advantage of utilizing zebrafish as the animal 
model for investigating anti-obesity is that they have 
approximately 70% homology with human genes and are 
sensitive to many pharmacological manipulations. 
Additionally, the use of zebrafish as the animal model is 
cost effective. More importantly, clinical evidence of 
hypolipidemic drugs exhibiting a significant hypolipidemic 
effect has been reported in zebrafish as well as in humans 
(Den Broeder et al. 2015; Kalueff et al. 2014; Leibold & 
Hammerschmidt 2015; Oka et al. 2010; Zang et al. 2018; 
Zhou et al. 2015). These characteristics suggest that 
zebrafish is an excellent model for pathological studies 
related to the lipid metabolism. We therefore applied HFD 
induced obese zebrafish in our experiment. To confirm our 
hypothesis of EC rhizomes as an anti-obesity agent, we 
monitored the mean body weight, body mass index (BMI), 
as well as biochemistry parameters of HFD-induced obese 
zebrafish fed with different ECEE-HFD mixtures for 3 
weeks. In addition, phytochemical screening, in vitro 
inhibition of pancreatic lipase enzyme (PLE), and gene 
expression analysis in visceral adipose tissue (VAT) of 
obese zebrafish were also evaluated.
MATERIALS AND METHODS
PLANT MATERIALS
Fresh rhizomes of EC were collected from Punggaluku, 
Southeast Sulawesi, Indonesia (in July 2018) and were 
identified by a taxonomist at the Herbarium Bogoriense, 
Research Centre for Biology, Indonesian Institute of 
Sciences, Bogor, Indonesia (accession number 2605/
IPH.1.01/If.07/XII/2018). The rhizomes were washed 
under tap water and then sliced to 1-2 mm width. The sliced 
rhizomes were then dried in a controlled oven at 45oC. The 
dried EC rhizomes were grounded into powder using a 
grinder. The powder of the EC rhizomes was macerated in 
ethanol 96% v/v for 24 h. This procedure was repeated 
three times. 
ANIMAL AND MAINTENANCE
Male zebrafish age 3-5 months were used in this study. 
The fishes were nurtured and maintained at 28°C in a 14:10 
hrs light/ dark cycle. The fishes were fed twice daily (10 
mg/fish/day) with standard commercial dried food (Tetra 
Bits Complete, Korea). 
METHODS
IN VITRO INHIBITION OF PANCREATIC LIPASE ENZYME 
(PLE) ASSAY
The in vitro inhibition of PLE assay was performed as 
described in Yuniarto et al. (2018). The substrate emulsion 
was prepared by dissolving 15 µL of sesame oil and 10 mg 
of BSA in phosphate buffer solution (PBS) (pH8.0) and the 
mixture was then sonicated for 5 min. Subsequentially, the 
substrate emulsion was mixed with 50 μL PLE and 10 μL 
of sample at various concentrations (10, 20, 40, 60, 80 and 
100 μg/mL). The mixtures were then incubated (30 min, 
37°C). After 30 min, the reactions were stopped by adding 
3 mL of 1:1 (v/v) chloroform and n-heptane solution. The 
mixtures were further centrifuged (2000 rpm, 10 min). The 
upper or aqueous layers were removed while the bottom 
layers were collected and reacted with a copper reagent. 
Next, the mixtures were further centrifuged (2000 rpm, 10 
min) to separate the organic layer. Finally, 0.5 mL of the 
organic layers were added with diethyldithiocarbamate-Na 
solution and the absorbances were measured at maximum 
λ of 480 nm by using a UV-Vis spectrophotometer 
(Beckman coulter DU 720, California, America). The 
percentage of PLE inhibitory activity was calculated using 
the following formula:
% PLE inhibitory activity
 × 100%
The absorbance of control contained a mixture of enzyme 
and substrate, whereas the absorbance of the sample 
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contained a mixture of enzyme, substrate and sample. 
Orlistat 0.25 μg/mL was used as positive standard.
IN VIVO ANTI-OBESITY ASSAY
Experimental Design
Three to five months old male zebrafish were purchased 
from Shifa Aquarium Bogor, West Java, Indonesia. After 
allowing two weeks for adaptation, the zebrafish were 
randomly assigned to five groups (n=15/group): normal 
diet/negative control group, high fat diet (HFD) group, HFD 
at 10% w/w ECEE, HFD at 20% w/w ECEE, and orlistat 
(positive control group) at 0.06% w/v. The dose of orlistat 
was chosen in accordance with a positive anti-obesity result 
prior to the experiment. The experimental design was 
carried out as presented in Figure 1. All groups were 
anesthetized under hypothermia condition before induction 
with HFD. Starting from the 4th week after HFD feeding, 
HFD-ECEE at 10% w/w and 20% w/w was fed for 3 weeks. 
The mean body weight and BMI were monitored once a 
week. After 3 weeks of HFD-ECEE feeding, the zebrafish 
were fasted for 14 h and then sacrificed under anesthesia. 
Blood was taken from the dorsal aorta using a heparinized 
needle and collected in a microtube (Landgraf et al. 2017; 
Meguro & Takahiro 2018; Neia et al. 2018). All 
experimental procedures involving the animals were 
conducted in accordance with The Laboratory Zebrafish 
guidelines (Harper & Lawrence 2011) and approved by 
the Research Ethics Committee of Padjadjaran University, 
Bandung, Indonesia (approval number 29/UN6.C10/
PN/2019).
MEASUREMENT OF BLOOD GLUCOSE AND 
TRIGLYCERIDES LEVELS
The blood glucose levels were determined using a 
glucometer (Autocheck, General Life Biotechnology, New 
Taipei, Taiwan). The serum triglyceride levels were 
determined using a commercial kit (Dialab-Triglyceride 
Kit (Dialab, Wiener Neudorf, Austria). The serum was 
mixed briefly with lipase and a triglyceride reaction 
mixture at 37°C for 5 min. The absorbance was then 
measured at λ 550 nm using a microplate reader.
FIGURE 1. Induction and treatment design of anti-obesity activity of ECEE-HFD in HFD-induced obese zebrafish
TABLE 1. Feed ingredients of experimental diets
Ingredients Normal diet (% w/w) High fat diet (% w/w)
Commercial dried food 100 55
Corn oil - 20
Egg yolk - 25
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mRNA EXTRACTION AND QUANTITATIVE REAL-TIME  
PCR
For total RNA extraction, adipose tissues of zebrafish were 
immersed in RNAlater (Qiagen, Hilden, Germany) at 4°C 
for a number of days. After bead-homogenization, total 
RNAs were isolated using an RNAeasy mini kit (Qiagen, 
Hilden, Germany). cDNA synthesis from 500 ng total RNA 
was performed using a ReverTra Ace qPCR RT Kit 
(Toyobo, Osaka, Japan). Quantitative real-time PCR (qPCR) 
was performed in cDNA samples using a Thunderbird 
SYBR qPCR mix and a qTOWER-3 real-time PCR thermal 
cyclers (Analytik Jena, Jena, Germany) in accordance with 
the manufacturer’s instructions. The sequences of the sense 
and antisense primers used for amplifications are shown 
in Table 2. The relative mRNA expression levels were 
determined using endogenous standard (β-actin). 
STATISTICAL ANALYSIS
All data are expressed as mean ± SD (standard deviation). 
Statistical analyses were performed using the SPSS 
Statistics 22 software (IBM Corporation, North Castle, New 
York, USA). Statistical comparisons were assessed by one-
way ANOVA followed by LSD’s multiple comparison test 
with a significance value of p <0.05 and p <0.01.
RESULTS 
PLE INHIBITORY ACTIVITY AND PHYTOCHEMICAL 
SCREENING
It was showed that the ECEE inhibited PLE activity. As can 
be seen in Table 3, ECEE inhibited PLE in a concentration 
dependent manner. The ECEE inhibited PLE activity by 
34.08, 38.65, 41.83, 45.24, 48.14, and 53.89 % at 
concentrations of 10, 20, 40, 60, 80 and 100 µg/mL in vitro, 
respectively. Orlistat, a pancreatic lipase inhibitor used as 
an anti-obesity agent, inhibited the PLE enzyme activity 
by 51.89% at 0.25 µg/mL. The ECEE had IC
50
 value of 
85.15 µg/mL. The preliminary phytochemical screening 
on ECEE (Table 4) obviously detected the presence of 
flavonoid and phenolic compounds. 
AMELIORATIVE EFFECT OF ECEE IN HFD-INDUCED 
OBESE ZEBRAFISH
The in vitro PLE assay demonstrated the potency of ECEE 
as an anti-obesity agent. It was then confirmed in the animal 
model. As seen in Figure 2, after induction with HFD, the 
obese zebrafish showed enlarged abdomen (Figure 2(b)). 
In addition, as also shown in Figure 3, the mean body 
weight (Figure 3(a)) of the positive control of the HFD-
TABLE 2. Primer pair sequences, accession number and product size of the studied genes
Gene name Accession Number Forward primer Reverse primer Product size (bp)
Pparg NM_131031.2 CGTCTTCATC CTCACTGAAC GCAGTATTGG CACTTGTTGC 191
adipoqb NM_001045425 CCACTATGAT GATGTTTCCG CTTGTCGTTC TTGTAGAGAC 184
β-act NM_131031.2 CCATTGAGCA CGGTATTGTG GGTCTCGAAC ATGATCTGTG 170
TABLE 3. PLE inhibitory activity of ECEE
Treatment Percentage inhibition (%) IC
50
 (µg/mL)
Control -
85.15
ECEE 10 µg/mL 34.08 ± 1.20*
ECEE 20 µg/mL 38.65 ± 1.75*
ECEE 40 µg/mL 41.83 ± 4.45*
ECEE 60 µg/mL 45.24 ± 5.52*
ECEE 80 µg/mL 48.14 ± 4.40*
ECEE 100 µg/mL 53.16 ± 3.04*
Orlistat 0.25 µg/mL 51.89 ± 2.87*
TABLE 4. Phytochemical screening of ECEE rhizome
Compound class Present/Absent
Alkaloids Absent
Flavonoids Present
Tanins Absent
Phenols Present
Steroids/Triterpenoids Absent
Quinons Absent
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induced obese zebrafish group increased from 0.264 ± 
0.014 g to 0.373 ± 0.100 g after week 3, whereas after 
week 6 the mean body weight increased up to 0.449 ± 
0.078 g. Calculation of BMI showed that the BMI values 
increased from 0.030 ± 0.003 g/cm2 to 0.032 ± 0.006 g/
cm2 and 0.035 ± 0.006 g/cm2 after week 3 for negative and 
positive control group, respectively (Figure 3(b)). Oka et 
al. (2013) state that a male zebrafish is considered obese 
when the BMI value is 1.1 folds greater than that of the 
negative control group. Our results obviously show that 
after week 3, the positive control of the HFD-induced obese 
zebrafish group had a BMI value greater by 1.2 folds than 
negative control group, indicating HFD caused obesity in 
the male zebrafish after 3 weeks of induction.
The confirmation of anti-obesity activity of ECEE was 
carried out in HFD-induced obese zebrafish fed with 10% 
w/w and 20% w/w ECEE-HFD for three weeks. As shown 
in Figure 3, after the fourth week of the experimental 
period, the mean body weight (Figure 3(a)) of the HFD-
induced obese zebrafish groups fed with 10% w/w and 
20% w/w ECEE-HFD were 0.332 ± 0.049 and 0.358 ± 0.099 
g with BMI values of 0.032 ± 0.004 and 0.034 ± 0.007 g/
cm2, respectively. These results obviously show an 
ameliorative effect on body weight compared to positive 
control group (mean body weight at 0.449 ± 0.078 and 
BMI at 0.039 ± 0.005). The HFD-induced obese zebrafish 
groups fed with 10% w/w and 20% w/w ECEE-HFD for 
the following 2 weeks (weeks 5 and 6), clearly showed 
stabilization of mean body weight and BMI. More 
importantly, after the sixth week of the experimental 
period, the mean body weight and BMI of the HFD-induced 
obese zebrafish group fed with 20% ECEE-HFD were below 
of those negative control/non-diet group and similar with 
those of the group fed with orlistat at 0.06% w/v. 
EFFECTS OF ECEE ON THE TRIGLYCERIDES AND BLOOD 
GLUCOSE LEVELS
Supplementation of HFD-induced obese zebrafish with 
ECEE resulted a significantly (p <0.05) lower levels of the 
serum triglycerides and blood glucose compared with that 
of the HFD group. As shown in Figure 4(a), 3-weeks 
supplementation of 10% w/w and 20% w/w ECEE reduced 
the triglycerides level by 40.0±1.64% and 51.4±4.53%, 
respectively, compared with the HFD group. Whereas the 
blood glucose levels were reduced from 124.40 ± 25.30 
mg/dL to 91.60 ± 13.3 mg/dL and 112 ± 22.02 mg/dL in 
group fed with 10% w/w and 20% w/w ECEE, respectively. 
EFFECTS OF ECEE ON THE EXPRESSION OF LIPID 
METABOLISM GENES IN VISCERAL ADIPOSE TISSUE 
Effects of ECEE on the expression of lipid metabolism 
genes in VAT are presented in Figure 5. As shown, the 
expression levels of PPARγ (a regulator of adipocyte 
differentiation) were significantly (p <0.01) lower in the 
10% w/w and 20% w/w ECEE-HFD group. In addition, as 
expected the expression levels of adiponectin (adipoqb, an 
antilipogenic protein) in were significantly (p <0.01) 
increased. Our data are similar with a study of anti-obesity 
activity on the HFD-induced obese zebrafish (Zang et al. 
2014).
DISCUSSION
In this study, we evaluate the anti-obesity and hypolipidemic 
effects of ECEE in HFD induced obese zebrafish. The results 
showed that the mean body weight gain of the HFD group 
zebrafish was significantly (p <0.01) higher than in the 
normal/negative control group, and the mean body weight 
 
 
 
 
 
       
 
FIGURE 2. Difference in appearance of normal zebrafish (a) and HFD-induced obese zebrafish (b) after week 3 of induction
FIGURE 3. Body weight (a), BMI (b) change during experimental period for six weeks. Level of significance                                     
* = p <0.05, ** = p <0.01
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of the 10% w/w and 20% w/w ECEE-HFD groups were 
ameliorated to that of negative control group. There were 
significant differences among the groups towards HFD 
group (Figure 3(a)). It should be noted that the ECEE 
exhibits PLE inhibitory activity. When PLE is blocked, it 
also blocks the hydrolyzation of triglycerides, thus 
reducing the production as well as absorption of free fatty 
acids. Therefore, the ameliorative effect on mean body 
weight in HFD induced obese zebrafish was probably due 
to low absorption of free fatty acids as an impact of PLE 
inhibition. In addition, the anti-obesity activity of ECEE 
appeared to be dose dependent. On the basis of this factor, 
we suggest that consuming 20% w/w ECEE obtains the 
same effect with orlistat.
The presence of phenolic and flavonoid compounds 
was detected in ECEE. Some flavonoid and phenolic 
compounds including galangin, diarylheptanoid, 
hesperidin, neohesperidin, licochalcone, orientin, 
yakuchinone A, and quercetin are reported having anti-
obesity potency (Buchholz & Melzig 2015; Kumar & 
Alagawadi 2013; Lin et al. 2013; Yang et al. 2014). Thus, 
the combination of flavonoid and phenolic compounds in 
ECEE could be responsible for the lower body weight gains 
in the ECEE groups. However, further identification and 
structure elucidation of the bioactive compounds in ECEE 
as anti-obesity agent are urgently needed.
Obesity and insulin resistance are found at an early 
stage of some metabolic syndromes (Klein & Romijn 
2017). Under high fat feeding or obesity condition, the 
release of free fatty acids from adipocytes promotes hepatic 
gluconeogenesis, then decreasing blood glucose disposal 
and inducing insulin resistance (Czech 2017; Storlien et 
al. 1986). The presence of insulin resistance can induce 
metabolic syndromes such as obesity, T2DM, and 
dyslipidemia (Choi et al. 2016; Czech 2017; Landgraf et 
al. 2017). Hence, to confirm this relationship and the 
potency of ECEE to prevent metabolic syndrome, we also 
evaluated the biochemistry parameters, i.e. the serum 
triglycerides and blood glucose levels. As shown in Figure 
4, the HFD induced obese zebrafish obviously displayed 
an increment of serum triglycerides and blood glucose 
levels after the sixth week. The HFD induced obese 
zebrafish groups fed with 10% w/w and 20% w/w ECEE-
HFD displayed a significant (p <0.05) reduction of 
triglycerides and blood glucose levels. This indicates that 
consumption of ECEE decreased triglycerides level by 
 
 
 
 
 
       
 
FIGURE 4. Triglyceride (a) and blood glucose (b) levels of HFD-induced obese zebrafish fed with 10% w/w and 20% w/w ECEE-
HFD at week 6 of the week experimental period. Level of significance * = p <0.05, ** = p <0.01
 
 
 
 
 
       
 
FIGURE 5. Effect ECEE on gene expression in visceral adipose tissue of zebrafish. Level of significance* = p <0.05 vs HFD 
group,** = p <0.01 vs HFD group. Adipoqb: Adiponectine b; pparg: peroxisome proliferator-activated receptor gamma
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reducing production of free fatty acid and excreting lipid 
accumulation as the results of PLE inhibition. Therefore, 
consumption of ECEE increased the blood glucose disposal, 
as normalization impact of serum triglycerides level as 
well as insulin sensitivity. A direct comparison between 
the HFD-induced obese zebrafish groups fed with 10% w/w 
and 20% w/w ECEE-HFD clearly showed that the group 
fed with 10% w/w ECEE-HFD had better reduction of blood 
glucose levels. The pharmacology activities of natural 
product extract can result from synergistic, additive, or 
antagonistic compounds consist in the extract. Hence, the 
greater blood glucose lowering effect of ECEE at 10% w/w 
is probable due to less antagonistic compound content 
consists in ECEE (Caesar & Cech 2019).
Supplementation of 10% w/w and 20% w/w ECEE-
HFD shows reduction of triglycerides level (Figure 4(a)), 
attenuation mRNA expression of PPARγ (a lipid peroxidation 
marker) and increment of adiponectin (Figure 5) in HFD 
induced zebrafish. PPARγ is a master regulator and a 
transcriptional factor that is involved in the last stage of 
adipogenesis. Consumption HFD promotes production of 
free fatty acids and triglycerides in adipose tissue (AT) 
(Kersten 2001), thus, increasing PPARγ gene expression 
in obesity. When PPARγ gene expression increases, 
adiponectin expression is further reduced (Balsan et al. 
2015; Grygiel-Gorniak 2014). It is also known that PPARγ 
is largely expressed in adipose tissue and important for 
regulation of adipose tissue lipid metabolism in muscle 
and liver. Our data demonstrate the potency of ECEE 
decreasing triglycerides accumulation and cascading of 
the transcriptional factor, i.e. PPARγ at the mRNA, which 
makes it capable of preventing metabolic syndromes by 
targeting adipogenesis (Balsan et al. 2015; Inoue et al. 
2005; Nakayama et al. 2018; Park et al. 1997; Sikder et al. 
2018; Tian et al. 2013). 
Some flavonoids are reported could improve 
dyslipidemia, partially by regulating fatty acids and 
cholesterol metabolism through decreasing adipocytes 
PPARγ expression in T2DM. In the basis of the presence of 
flavonoid and phenolic compounds, we propose that 
molecular mechanism of dyslipidemia attenuation of ECEE 
is partially by inhibition of PLE and targeting PPARγ. 
Overall, our results recommend that ECEE can be 
considered as a potential alternative treatment for 
controlling obesity as well as related diseases including 
T2DM and cardiovascular.
CONCLUSION
In conclusion, based on physiological, biochemical, in vitro 
and in vivo analyses, this study demonstrated that ethanolic 
extract of EC rhizome has potent anti-obesity activities. 
ECEE exerts anti-obesity effects by inhibiting lipase 
enzyme activity. The proposed molecular mechanism is 
adiponectin and PPARγ targeting. Finally, we suggest that 
ECEE can be used as a potential therapeutic alternative for 
the treatment of obesity.
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